Background
==========

Chronic myeloid leukemia (CML) is a clonal hematopoietic stem cell proliferation-induced myeloproliferative disease \[[@b1-medscimonit-24-5668]\]. It has high heterogeneity and distinct molecular genetic features -- the unique cytogenetic features of CML are Philadelphia chromosome t (9; 22) (q34; q11) -- in which the c-ABL protooncogene on the long arm of chromosome 9 translocates to the BCR of the long arm of chromosome 22, forming an BCR-ABL fusion gene \[[@b2-medscimonit-24-5668],[@b3-medscimonit-24-5668]\], and it has become an important topic of research. Imatinib mesylate and the newer BCR-ABL tyrosine kinase inhibitors are the standard therapy for CML \[[@b4-medscimonit-24-5668]\], which greatly improves the survival of patients with chronic myeloid leukemia; however, drug resistance and adverse effects remain a problem \[[@b5-medscimonit-24-5668]\]. Therefore, looking for new strategies to improve the treatment of chronic myeloid leukemia treatment has important clinical significance.

Chinese herbal medicine is a unique medicine used in Chinese medicine to prevent and treat diseases. With the development of medicine around the world, China's ancient Chinese medicine system is receiving the attention of the world. However, it is the most important and difficult task for Chinese traditional medicine to elucidate the interaction between the complex chemical systems of traditional Chinese medicine and the complex systems of diseases and syndromes. Qingdai is prepared as clumps of dry powder, obtained by machining the leaves or stems of *Strobilanthes cusia*, *Polygonum tinctorium Ait*, and *Isatis indigotica Fort* (Pharmacopoeia of the People's Republic of China, 2010). Qingdai is one herb in Qing Huang San, which has been recorded in the "Jing Yue Quan Shu," "Shi Yi De Xiao Fang," "Qi Xiao Liang Fang," and so on, and is Professor Zhou Aixiang's classical prescription of CML treatment \[[@b6-medscimonit-24-5668]\]. As confirmed by research, indirubin, a component of Qingdai, is indeed effective in the treatment of chronic myeloid leukemia \[[@b7-medscimonit-24-5668]\]. Dai et al. treated K562 cells with different concentrations of Qingdai compound (2.5, 5, 7.5, 10, and 20 ug/ml) and harvested them at 24 h, reporting that the Qingdai compound inhibited proliferation and promoted apoptosis in K562 cells. Then, the expression of bcr/abl and JWA was detected by semi-quantitative RT-PCR, and concentration-dependent decreases were found in bcr-abl and JWA expression of K562 cells. It was proved that the Qingdai compound can partially promote the apoptosis of K562 cells by inhibiting the expression of bcr/abl and JWA in K562 cells \[[@b8-medscimonit-24-5668]\]; however, its specific mechanism needs further study. Therefore, it is necessary to develop a novel strategy to understand the biological processes of the interactions among drugs, genes, and proteins at a systems level in order to discover the molecular mechanisms related to the therapeutic efficacy of TCM.

In recent years, with the continuous innovation and development of systems biology, network pharmacology and molecular docking provide feasible research strategies for exploring the intrinsic principles of effective intervention of traditional Chinese medicine (TCM) components and building multi-target precise treatment modes for TCM \[[@b9-medscimonit-24-5668],[@b10-medscimonit-24-5668]\]. It has been successfully applied to the molecular network level understanding of the pharmacological mechanism of TCM. For example, in the treatment of diabetes mellitus, Huangqi and Huanglian showed the synergistic mechanism \[[@b11-medscimonit-24-5668]\], and through these research strategies we demonstrated the important pharmacological mechanism of Yin huang Qing fei capsule in treating chronic bronchitis \[[@b12-medscimonit-24-5668]\].

We based the present study on network pharmacology strategies to decipher the pharmacological mechanisms of Qingdai acting on CML. We offer a systems strategy: (1) We collected the chemical components of Qingdai and downloaded structure and screening index data; (2) We predicted putative targets of Qingdai and analyzed putative targets by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis; (3) We collected the known therapeutic targets of drugs in the treatment of CML; (4) We analyzed and investigated the network between putative targets of Qingdai and known therapeutic targets of CML, which provide a strategy for the further study of the pharmacological mechanism of Qingdai on CML; (5) We performed molecular docking between the molecular compounds of Qingdai and the major targets to validate our findings using a computer-aided drug design method. We expected to achieve our experimental goals with this series of experimental methods.

Material and Methods
====================

The technical strategy of this research is shown in [Figure 1](#f1-medscimonit-24-5668){ref-type="fig"}.

Data preparation
----------------

### Active compounds of Qingdai

Compositive compounds of Qingdai were obtained from TCMSP Database and Literature database. TCMSP (*<http://ibts.hkbu.edu.hk/LSP/tcmsp.php>*), updated in 2014-05-31) \[[@b13-medscimonit-24-5668]\], which is based on the framework of systems pharmacology for herbal medicines, consists of all the 499 Chinese herbs registered in the Chinese pharmacopoeia with 29 384 ingredients and 12 important ADME-related properties are provided for drug screening and evaluation. Then, through literature mining to prevent omissions, we set the criteria of OB greater than 30%, DL greater than 0.18, and Caco-2 greater than −0.14. When they met these criteria, these components were used as candidate compounds for further analysis. We collected information on 7 compounds and obtained the name of the molecule and its chemical structure. We obtained the molecular Smiles format through the PubChem (*<https://pubchem.ncbi.nlm.nih.gov/>*) database.

### Known therapeutic targets of drugs in the treatment of chronic myelocytic leukemia

The known therapeutic targets of drugs in the treatment of chronic myeloid leukemia were obtained in 3 ways: PubMed (*<https://www.ncbi.nlm.nih.gov/pubmed>*,2017-7-31), DrugBank20 (*<http://www.drugbank.ca/>*, version 5.0.10, released 2017-11-14), and the Online Mendelian Inheritance in Man (OMIM) database (<http://www.omim.org/>, released on 2017-12-20) \[[@b14-medscimonit-24-5668]\]. In the PubMed database, "chronic myeloid leukemia" was retrieved, and the restriction was "gene" and "Homo sapiens." We verified the accuracy of the genes by consulting the literature related to these genes. In total, 252 known therapeutic targets of CML were chosen. In DrugBank, in order to improve accuracy, only the drugs that are approved by the Food and Drug Administration (FDA) and whose targets are human genes/proteins were selected, then we chose 265 targets for treating CML. In addition, when searching the OMIM database for "chronic myeloid leukemia" as a keyword, we collected 274 known therapeutic targets. After combining the data from these 3 databases and removing the duplicates, a total of 729 known targets for CML treatment were used for the next analysis. [Supplementary Table 1](#s1-medscimonit-24-5668){ref-type="supplementary-material"} provides detailed information on these known therapeutic targets. We converted different types of ID proteins to UniProt IDs. To elucidate the signaling pathways involved in known therapeutic targets of CML, we used DAVID (Database Visualization and Integrated Discovery software, *<http://david.abcc.ncifcrf.gov>* version 6.7) and KEGG (Kyoto Encyclopedia of Genes and Genomes database, EGG, *<http://www.genome.jp/kegg/>*, updated on April 18, 2016) to perform enrichment pathways. The top 10 significant pathway terms were pathways in cancer, MAPK signaling pathway, natural killer cell-mediated cytotoxicity, Jak-STAT signaling pathway, cytokine-cytokine receptor interaction, chronic myeloid leukemia, prostate cancer, focal adhesion, ErbB signaling pathway, and neurotrophin signaling pathway.

### Prediction of targets of Qingdai

Obtaining the target of Qingdai through experiments requires a great deal of manpower, material, and financial resources. To accurately predict the targets of bioactive molecules based on a combination of 2D and 3D similarity measures with known ligands, we used the web server Swiss Target Prediction (*<http://www.swisstargetprediction.ch/>*) to predict the putative targets of the active compounds of Qingdai. Predictions can be carried out in 5 different organisms, and mapping predictions by homology within and between different species is enabled for close paralogs and orthologs \[[@b15-medscimonit-24-5668]\]. The "smiles" formats of 7 active compounds were imported into Swiss Target Prediction to predict their putative targets of action. It is noteworthy that the predicted putative target is limited to Homo sapiens, and to improve the reliability of predictions goal, only a high probability of target selected. A total of 112 therapeutic putative targets were obtained. All putative targets obtained were sent to Therapeutic Target Database (TTD) (*<http://bidd.nus.edu.sg/group/cjttd/>*, 2015-09-10), Comparative Toxicogenomics Database (CTD) (*<http://ctdbase.org/>*, 2017-12-05), and PharmGKB (*<https://www.pharmgkb.org/>*) to determine whether these putative targets have some connection to CML. To further understand the putative target of Qingdai, GO enrichment analysis and KEGG pathways analysis were performed.

Network construction
--------------------

Three types of visual networks were built:

1.  The compound-target network (C-T network) is an interaction network using the active compounds of Qingdai and its corresponding putative targets.

2.  The target-pathway network (T-P network) is composed of the putative targets and corresponding pathways.

3.  The target-target network (T-T network) was built using the relationship between the putative targets of Qingdai and known therapeutic targets of the CML.

Cytoscape 3.5.1 (*<http://www.cytoscape.org/>*) is an open software application for visualizing, integrating, modeling, and analyzing interactive networks. All the networks were built using it.

**Analysis of the target-target network** (Qingdai putative target-known therapeutic targets of the CML network).

Li et al. \[[@b16-medscimonit-24-5668]\] suggested that "If the degree of a node is more than 2 times the median degree of all the nodes in a network, the node may function as a big hub." The topological features of the target-target network are analyzed by several important topological properties, such as "degree" \[[@b17-medscimonit-24-5668]\], "betweenness" \[[@b17-medscimonit-24-5668]\], "closeness" \[[@b17-medscimonit-24-5668]\], and "coreness" (an iterative process in which nodes are removed from the network with minimal connection order) \[[@b18-medscimonit-24-5668]\]. The larger a protein's degree/node betweenness/closeness centrality, the more important that protein is in the PPI network \[[@b19-medscimonit-24-5668]\]. Subsequently, the targets were screened for topological importance. Then, the major hubs were screened. The DAVID webserver was used to perform KEGG pathway enrichment analysis of the main targets.

### Molecular docking simulation

We used computer molecular docking simulation techniques to verify the credibility of the study. SystemsDOCK (*<http://systemsdock.unit.oist.jp/>*) was used for molecule docking \[[@b20-medscimonit-24-5668]\]. SystemsDock is a web server for network pharmacology-based prediction and analysis that permits docking simulation and molecular pathway mapping for comprehensive characterization of ligand selectivity and interpretation of ligand action on a complex molecular network. All the compounds and 3D structures of Qingdai were directly downloaded from the PubChem database (*<https://pubchem.ncbi.nlm.nih.gov/>*, 2017-11-26), and we obtained the 3D structures of target genes from Uniprot (*<http://www.uniprot.org/>*, 2017-11) and PDM databases (*<http://www.rcsb.org/pdb/home/home.do>*). Docking scores were used to assess the binding affinities of compounds to the respective candidate target.

Results
=======

Active compounds in Qingdai
---------------------------

A single Chinese medicine contains a large number of compounds, so it is helpful to identify these active compounds by means of network pharmacological virtual screening. A total of 53 compounds in Qingdai were obtained. Then, 3 ADME (absorption, distribution, metabolism, and excretion)-related models, including OB, DL, and Caco-2, were used to screen most of the active compounds from Qingdai. Finally, we selected 7 compounds from Qingdai ([Table 1](#t1-medscimonit-24-5668){ref-type="table"}), and after text mining, found that most of these compounds possess potent pharmacological activities, such as indirubin, the main active and characteristic compound in Qingdai. Research shows that indirubin and its derivatives can be used to treat chronic myelogenous leukemia by potently inhibiting the Signal Transducer and Activator of Transcription 5 (Stat5) protein in CML cells \[[@b21-medscimonit-24-5668]\], and indirubin and its derivatives could have anti-angiogenic activity \[[@b22-medscimonit-24-5668]\]. Studies on Qingdainone have shown anti-tumor and anti-inflammatory effects \[[@b23-medscimonit-24-5668]\]. Quindoline can cause cell cycle arrest, resulting in inhibition of cell proliferation and causing cell apoptosis \[[@b24-medscimonit-24-5668]\]. Bisindigotin was found to dose-dependently inhibit TCDD-induced ethoxyresorufin O-demethylase (EROD) activity to achieve an anti-tumor effect \[[@b25-medscimonit-24-5668]\]. Isoindigo can mediate the cell proliferation pathway to promote apoptosis \[[@b26-medscimonit-24-5668],[@b27-medscimonit-24-5668]\]. Beta-sitosterol could inhibit the growth of bacteria and was found to be anti-inflammatory \[[@b28-medscimonit-24-5668]\]. Indirubin and Indigotin were determined to be the quality markers of Qingdai in the Chinese Pharmacopoeia (The State Pharmacopoeia Commission of China, 2015).

Putative targets of Qingdai
---------------------------

For Qingdai, through putative target prediction for the 7 components, a total of 112 targets were obtained. Cyclin-dependent kinases (CDKs) are involved in regulating both cell cycle and transcription. Indirubin inhibits CDK activity by K562 cell cycle arrest and promotes apoptosis \[[@b29-medscimonit-24-5668],[@b30-medscimonit-24-5668]\]. With Quindoline, through prediction, MAPKs (mitogen-activated protein kinase) and CLKs were obtained. MAPKs play key roles in many cell proliferation-related signaling pathways \[[@b31-medscimonit-24-5668]\]. Research by Ahmed K found in cancer cells that CLKs control the supply of full-length, functional mRNAs coding for a variety of proteins essential for cell growth and survival. Thus, inhibition of CLKs might become a novel anticancer strategy, leading to a selective depletion of cancer-related proteins after turnover \[[@b17-medscimonit-24-5668]\]. β-sitosterol has antioxidant activity in a complex system \[[@b32-medscimonit-24-5668]\]. Interestingly, 28 of the 112 putative target genes are common targets for one or more of these components, indicating that these components may be acting on some of the same biological processes or pathways, which reflects a synergistic effect between the individual components of TCM.

The C-T network was constructed to visualize and explain the complex relationship between the active compounds of Qingdai and its putative targets ([Figure 2](#f2-medscimonit-24-5668){ref-type="fig"}).

GO enrichment and KEGG pathway analysis of the putative targets
---------------------------------------------------------------

The GO and KEGG enrichment analysis were used to comment on the 112 putative targets of Qingdai. As shown in the results of the enrichment, a total of 433 GO enrichment results were obtained, including biological process (BP) (310 terms), molecular function (MF) (86 terms), and cellular component (CC) (38 terms). We set the level of statistical significance at P\<0.05. Then, the top 10 significantly enriched terms were selected in the BP, MF, and CC categories listed in [Figure 3](#f3-medscimonit-24-5668){ref-type="fig"}. GO enrichment analysis showed that Qingdai can inhibit protein kinase phosphorylation and protein kinase to inhibit cell proliferation, block the cell signaling pathway to inhibit cell proliferation, and promote apoptosis. In addition, chemokines inhibit tumor growth and development by activating immunocompetent cytotoxic cells or inhibiting tumor-associated angiogenesis. In addition, Qingdai can be organized by cell division cycle of proliferation to inhibit cell proliferation or cell mitosis. In addition, it acts on GPCRs, which are closely related to biological behaviors such as the proliferation, invasion, and metastasis of tumors, involving the classical signal pathways such as ERK/MAPK \[[@b33-medscimonit-24-5668]\]. In recent years, studies have shown that it can serve as a new target for anti-tumor drugs \[[@b34-medscimonit-24-5668]\]. It is possible that the role of Qingdai on CML is through these molecular mechanisms.

The putative targets of active compounds were mapped onto the 26 KEGG pathways ([Figure 4](#f4-medscimonit-24-5668){ref-type="fig"}). The neuroactive ligand-receptor interaction pathway showed the highest number of target connections (count=13), and cytokine-cytokine receptor interaction with 12 targets, pathways in cancer with 11, and included the focal adhesion, cell cycle, chemokine signaling pathway, MAPK signaling pathway, and p53 signaling pathway, respectively. These pathways have well-established roles in the inhibition of tumor cell growth and differentiation and promote tumor cell apoptosis. In addition, there are numerous signaling pathways involved in immunity and inflammation, such as Toll-like receptor signaling pathways, T cell receptor signaling pathway, and Fc epsilon RI signaling pathway. These pathways play an important role in the infection caused by chronic myeloid leukemia. These pathways of the targets show that Qingdai has a therapeutic effect for a variety of malignant tumors, endocrine disease, and inflammatory diseases. Details are provided in [Table 2](#t2-medscimonit-24-5668){ref-type="table"}.

Pharmacological mechanisms of Qingdai acting on chronic myeloid leukemia
------------------------------------------------------------------------

The link between traditional Chinese medicine and disease is complex. To illustrate the basic relationship between them, the T-T network was performed for analysis. T-T network consisted of 571 nodes and 10 169 edges. The major hubs in the hub interaction network were determined by calculating 4 features: "degree," "node betweenness," "closeness", and "K value". There were 195 major hubs, including 32 Qingdai targets ([Table 3](#t3-medscimonit-24-5668){ref-type="table"}) and 168 known therapeutic targets of chronic myeloid leukemia. Interestingly, there were 11 targets that were common to both that were screened. Then, a network of major hubs based on their direct interactions was constructed ([Figure 5](#f5-medscimonit-24-5668){ref-type="fig"}).

To further decipher the pharmacological mechanism by which Qingdai affects CML, pathway enrichment analysis was performed using the KEGG pathway database. We found that the major hubs were significantly related to various physiological processes, mainly concentrated in 5 annotation clusters, including epidermal growth factor receptor signaling pathways for cell growth, proliferation, differentiation and metabolism, malignant pathways, immune and inflammation-related pathways, and angiogenesis-related pathways. Chronic myeloid leukemia is a malignant proliferative disease of bone marrow hematopoietic cells and is closely related with ErbB receptor overexpression \[[@b35-medscimonit-24-5668]\]. ErbB receptor signaling regulates cell proliferation, migration, differentiation, apoptosis, and cell migration through Akt, MAPK, and many other pathways. In many forms of malignancy in organs such as the breasts, ovaries, brain, and prostate gland \[[@b36-medscimonit-24-5668]\], members of the ErbB family, as well as some of their ligands, are often overexpressed, amplified, or mutated, making them an important therapeutic target \[[@b37-medscimonit-24-5668]\]. Immune and inflammatory signaling pathways include the Toll-like receptor signaling pathway, T cell receptor signaling pathway, B cell receptor signaling pathway, and Fc epsilon RI signaling pathway. TLR activation has been described to play a role in other leukemias, such as chronic lymphocytic leukemia \[[@b38-medscimonit-24-5668]\]. T cell receptor (TCR) activation can promote many signal transduction cascades and ultimately determine cell fate by regulating cytokine production, cell survival, proliferation, and differentiation \[[@b39-medscimonit-24-5668]\]. Regulatory T (Treg) cells can weaken anti-tumor immune responses, which could serve as a promising immuno-therapeutic approach for tumors \[[@b40-medscimonit-24-5668]\]. The Fc epsilon RI receptor induces multiple signaling pathways that control the secretion of allergic mediators and induction of cytokine gene transcription, resulting in secretion of various molecules: IL-4, IL-5, IL-6, IL-10, IL-13, INF-gamma (interferon-gamma), and TNF-alpha (tumor necrosis factor alpha) \[[@b41-medscimonit-24-5668]\]. We provide detailed information of the 20 most meaningful enrichment pathways in [Table 4](#t4-medscimonit-24-5668){ref-type="table"}.

Drug targets reported to be involved in CML pathogenesis for the treatment of CML are involved in cell cycle, growth inhibition, MAPK, ErBb, transforming growth factor beta, and p53 signaling pathways. Interestingly, the 32 Qingdai putative targets included in the major hubs of the T-T network were also included in these pathways. In addition, 32 putative targets were involved in immune and inflammation-related pathways, such as Toll-like receptor, NOD-like receptor, RIG-I-like receptor, and Fc epsilon RI T cell receptor signaling pathway.

To further explore the molecular mechanism of action of Qingdai on CML, we reviewed the literature on the role of Qingdai putative targets in these pathways. Qingdainone, bisindigotin, isoindigo, and indirubin all have target enrichment in the MAPK signaling pathway (MAPK14, MAPT, PDGFRA, PDGFRB, MAPK9, MAPK11, MAPK8, and MAPK10). CD Kang et al. showed that the inhibition of ERK/MAPK induced apoptosis in K562 cells \[[@b42-medscimonit-24-5668]\]. PDGFRA/B are oncogenes involving tyrosine kinases \[[@b43-medscimonit-24-5668]\]. Aberrant activity of PTK (protein tyrosine kinases) has been implicated in the stimulation of cancer growth and progression, the induction of drug resistance, tumor neovascularization, tissue invasion, extravasation, and the formation of metastases \[[@b44-medscimonit-24-5668]\]. We speculate that isoindigo in Qingdai inhibits CML by acting on PDGFRA/B. In the ErbB pathway, GSK3B plays a pivotal role in preserving quiescent HSCs, which has now opened new therapeutic avenues for understanding leukemic stem cell function \[[@b45-medscimonit-24-5668]\]. Through the cytokine-cytokine receptor interaction, cytokines act on the immune system and hematopoietic system and play an important regulatory role in cell--cell interactions, cell proliferation, differentiation, and effector functions \[[@b46-medscimonit-24-5668]\]. The p53 protein network regulates important mechanisms in DNA damage repair, cell cycle regulation/checkpoints, and cell senescence and apoptosis, as demonstrated by its ability to positively regulate the expression of various pro-apoptotic genes \[[@b47-medscimonit-24-5668]\]. In addition, research shows that p53 can stably induce CML cell apoptosis \[[@b48-medscimonit-24-5668]\]. Cyclin-dependent kinases (CDKS) are a family of serine/threonine kinases that have been firmly established as key regulators of transcription processes underlying coordinated cell cycle entry and sequential progression in nearly all types of proliferative cells \[[@b49-medscimonit-24-5668]\]. Infection with CML has important secondary symptoms. Enrichment pathways of Qingdai putative targets involve immune and inflammatory pathways, which activate the patient's own immune system and enhance the defence against sources of external infection, such as phagocytosis of immune cells, which plays an essential role in host defence mechanisms by enveloping and destroying infectious pathogens \[[@b41-medscimonit-24-5668]\].

In addition, some of the putative targets have a special role in CML. The FMS-like tyrosine kinase 3 (FLT3) gene encodes a class III receptor tyrosine kinase (RTK) that plays important roles in the proliferation, differentiation, and survival of hematopoietic stem and progenitor cells (HSPCs), and FLT3 is frequently mutated and overexpressed in hematologic malignancies \[[@b50-medscimonit-24-5668]\]. The AGM130 compound is derived from indirubin, which is known as a CDK inhibitor. Research shows that the AGM130 compound efficiently decreased the viability of CML-derived K562 cells, which suggests that AGM130 is a strong candidate for treating Imatinib-resistant CML \[[@b51-medscimonit-24-5668]\]. In addition, patients with ABCG2 diplotypes might be at higher risk for the rapid and severe development of CML and have a weaker response to treatments with imatinib \[[@b52-medscimonit-24-5668]\]. We hypothesize that it binds to ABCG2 to enhance the efficacy and reduce the risk of imatinib resistance.

On this basis, the major putative targets of Qingdai that are significantly associated with these biological processes and pathways might play a role in the treatment of CML.

Molecular docking validation
----------------------------

Molecular docking is a rapid method to predict the binding force between traditional Chinese medicine components and the target. It is based on the docking of the ligand and the acceptor's spatial structure. SystemsDock applies AutoDock VINA \[[@b53-medscimonit-24-5668]\] to perform docking simulation based on the characterized binding interaction and molecular properties \[[@b19-medscimonit-24-5668]\]. DocK-IN utilizes a machine learning algorithm (Random Forest) together with a series of characterized binding interactions and test compound molecular properties, usually ranging from 0 to 10 (from weak to strong binding) allowing a straightforward indication of binding strength \[[@b20-medscimonit-24-5668]\]. The 7 compounds of Qingdai and the corresponding candidate major targets were further validated by a molecular docking simulation. As a result, 23 pairs of components of Qingdai and candidate targets had binding efficiencies. Detailed information about the results of molecular docking are described in [Supplementary Table 2](#s2-medscimonit-24-5668){ref-type="supplementary-material"}. These findings require further experimental verification.

Discussion
==========

In the application of traditional Chinese medicine treatment of CML, Qingdai is given high priority for selection, and has been frequently used in TCM prescriptions. *In vitro* experiments clearly demonstrated that Qingdai has the ability to inhibit K562 cell proliferation and promote its apoptosis. We used modern network pharmacology and molecular docking technology to explain the effective substance basis and multi-targeting effect of Qingdai treatment of CML. The study of traditional Chinese medicine theory and value is based on the scientific methodology of systematic medicine and has the significance of integrating innovation. In our research, we screened 7 Qingdai active compounds and, from a total of 112 predicted targets of active compounds, obtained 32 major targets of Qingdai for treatment of chronic myeloid leukemia, and enriched 15 signaling pathways related to the treatment of CML. Then, we verified the results of our study by molecular docking. The present study shows the following:

1.  By predicting the targets of 7 compounds in Qingdai, we constructed a C-T network and performed GO analysis and KEGG analysis of the putative targets to provide clues to the pharmacology research of Qingdai.

2.  We constructed the Qingdai putative target-known therapeutic targets of the CML network, suggesting that Qingdai may affect the disease-related pathways of chronic myeloid leukemia by regulating its candidate targets, such as the cytokine-cytokine receptor interaction, cell cycle, p53 signaling pathway, MAPK signaling pathway, and immune system-related pathways.

3.  According to the molecular docking simulation, 23 pairs of components of Qingdai and corresponding putative targets had strong binding efficiencies.

Concusions
==========

Network pharmacology for the study of complex mechanisms of Chinese medicine intervention disease provides new ideas and new methods. This research explored the molecular mechanism of the effects of Qingdai on CML based on these ideas. Our study was based on bioinformatics analysis and computer simulation analysis. Further clinical application assessments and experimental validations for these predicted results are required.

Supplementary Tables
====================

###### 

known therapeutic targets of CML.

  ---------- ---------- ---------- --------- --------- -------------- ---------- ---------
  ESR1       MLL        IMD21      QACR      SLC2      LY75           SFRP1      PTK2B
  TP53       HRX        MME        ACRB      SLCO1B1   CBY1           LEF1       ELANE
  BCR        HTRX1      CD10       CNGA1     SLC22A8   ARHGAP26       DDIT3      
             WDSTS      CALLA      KCNMA1    POLB      ST3GAL1        GSTA1      PTCH1
  ABCB1      CBL2       NEP        CLCN2     CDA       MIR199B        MECOM      CD247
  MTHFR      NSLL       CMT2T      IL17A     NT5E      ST8SIA4        SRSF1      STAT5B
  TNF        CLLS5      SCA43      ADRB1     DCTD      ATG4B          CDKN1C     AICDA
  JAK2       FLI1       MLF1       TUBB1     ABCC10    MIRLET7I       MIR17      IDH2
  IL6        BDPLT21    LPP        CYP2E1    SLC29A1   PTBP2          CRK        AXL
  TGFB1      ETV6       CHIC2      VDR       1KBKG     SPRED2         GATA2      CDK9
  AKT1       TEL        BTL        MPL       PRKCA     OSBP2          NOTCH2     PMP22
  GSTM1      THC5       PBT        CHRM1     IMPDH1    DDX43          PRTN3      ADIPOR1
  CTNNB1     KRAS2      RAP1GDS1   CNRM2     IMPDH2    P2RX5          IL32       IKZF1
  KRAS       RASK2      TCS1       BCHE      PB1       MKNK2          MIR223     TET2
  GSTT1      NS         BST2       UREC      NT5C2     UBASH3B        IL24       MTHFD1L
  NFKB1      CFC2       DKCA2      MMP12     ENPP1     MIR30E         ARRB1      NFKB2
  BRCA1      RALD       DKCB4      NS5B      PRKCD     ATP5F1         PAX5       ERCC5
  MMP9       CMTS       PFBMFT1    ADRB2     MS4A1     KIR2DL5B       WSB1       DAPK1
  STAT3      PTPN11     CMM9       PTAFR     HCK       GAS2           CIP2A      POU2F1
  ABL1       PTP2C      LIFR       HRH1      CDK2      FAM27E5        KIF11      SPI1
  PTGS2      SHP2       SWS        NS5A      MAP2K1    ETNK1          MIR31      SLC22A1
  CDKN2A     NS1        STWS       ADRA2A    MAP2K2    MIR1301        BIN1       SEP9
  IL1B       JMML       SJS2       ADRA2B    MAP3K2    ST8SIA6        SET        
  MYC        METCDS     ACSL6      CHD1      1FNAR2    LOC107126288   JUP        
  GSTP1      CLLS2      FACL6      DRD2      POLA1     LOC107126281   REL        
  CXCL8      D13S25     ACS2       DRD1      SLC28A3   MIR564         HOXA9      
  LEP        DBM        IRF1       HTR2A     PARP1     MIR2278        CRKL       
  TERT       FLVCR2     MAR        OPRM1     PARP2     MIR4701        CSF3R      
  BCL2       C14orf58   GRAF       PDE4B     PARP3     ABL            SLCO1B3    
  IFNG       CCT        PDGFR      PANX1     CD22      GF1R           MTHFD1     
  MTOR       PVHH       IBGC4      CYP3N4    POLE      SPC            IFNAR1     
  XRCC1      EPV        IMF1       CASR      POLE2     EPHA2          EHMT2      
  FAS        SERPINA1   PENTT      KCND      POLE3     ICK            CDC6       
  CCND1      PI         KOGS       HTR7      POLE4     YES1           ADIPOR2    
  BIRC5      AAT        NSD1       ORM2      PNP       KIT            PER3       
  GSK3B      TCL1B      ARA267     SLC6A2    C3        FYN            KIR2DS2    
  MAPK14     TML1       STO        SMPD1     C4A       BTK            EPHB4      
  ATM        TCL1A      SOTOS1     HTR1A     C4B       NR4A3          MEF2C      
  MIR21      TCL1       CLLS4      NOMO1     C5        CSK            ASXL1      
  HMGB1      MYL        DEK        MAP2      AOX1      EPHA5          HES1       
  CYP1A1     CREBBP     D6S231E    PHD       DNMT1     FGR            KIR2DL2    
  NOTCH1     CBP        CTEPH1     CA2       SLC01A2   FRK            PRAME      
  KDR        RSTS1      HLA-B      NR1I2     HSD11B1   HSPA8          SMO        
  NFE2L2     MYH11      SPDA1      POMC      ALB       ZAK            ORM1       
  HLA-G      AAT4       HLA-DPB1   CALM1     RARA      PPAT           MSR1       
  CASP3      FAA4       TREM2      YARS      RARB      CYP3A4         NUMB       
  ABCG2      FUS        MYB        TAT       1KBKB     CYP1A2         CAMK2G     
  EZH2       TLS        ALL2       SLC16A2   TXNRD1    CYP1B1         CCDC170    
  CDKN1B     ALS6       MLSM7      TFPI      MAPK3     FM03           GPX3       
  JUN        ETM4       DEL7q      GNRHR     MAPK1     RET            MIR451A    
  ERCC2      CBFB       C7DELq     KCNQ2     CDKN1A    NTPK1          CDK7       
  TNFSF10    PEBP2B     NCF1       KCNQ3     HDAC1     CSF1R          MIR101-1   
  RHOA       DIA4       PRSS2      HTR3A     PML       DDR1           IRF8       
  WT1        NMOR1      TRY2       GRIA1     ADA       CYP3A7         KIR2DS4    
  PDCD1      CYBA       SCLL       GNB1      CD38      CYP2C9         ID4        
  LGALS3     NF1        NSD3       MRD42     CD19      CYP2D6         CD33       
  CYP3A5     VRNF       WHSC1L1    CTRC      RXRA      CYP2C19        KIR2DS1    
  CD274      WSS        SLC20A2    CLCR      RXRG      PTGS1          HMMR       
  KCNH2      NFNS       MLVAR      IMD22     1GFBP3    SLC22A2        SOCS2      
  LCN2       ERBB2      GLVR2      TPOR      PSG5      ABCA3          BLK        
  AURKA      NGL        IBGC1      MPLV      CSF2RA    CYP2C8         RMND1      
  RUNX1      NEU        NBN        THCYT2    1L3RA     UGT1A1         MIR224     
  LEPR       HER2       NBS1       TAL1      SDC2      GSTA2          RANGAP1    
  HSP90AA1   MSF        THCYT3     TCL5      PRG2      MGST2          FUT1       
  NPM1       MSF1       LALL       SCL       EPOR      FLT3           PCM1       
  AKAP12     NAPB       BSAP       BCL10     GPRC5A    RPI2           MIR130A    
  BCL2L1     SH3GL1     ALL3       IMD37     NROB1     RPL3           MIR7-1     
  MCL1       EEN        TAL2       GFI1      ALDH1A2   TEK            AHI1       
  IL2RA      LYL1       CLLS3      ZNF163    RARRES1   FGFR1          CDKN2C     
  PLK1       CEBPA      CHDSKM     SCN2      LCN1      FGFR2          ZBTB2      
  PTPN22     CEBP       NUP214     RBM15     OBP2A     FGFR3          PLCD1      
  XIAP       BCL3       D9S46E     SPEN      RBP4      FGFR4          MTSS1      
  BCL2L11    BAX        CAN        OTT       PDK4      LCK            MSI2       
  DPP4       TAM        CAIN       IGFR2     CYP26A1   SRC            FERMT3     
  SYK        MST        AF10       CD32      HPGDS     ABCB11         PIWIL1     
  PDGFRA     CBFA2      ALL1       PBX1      ATP1A1    FCGR3B         RAPGEF1    
  MIR155     AML1       MBL2       CAKUHED   DGUOK     C1R            MKNK1      
  TWIST1     CML        MBL        ABL2      1TGAL     C1QA           EHMT1      
  CBL        PHL        MBP1       ABLL      TOP2A     C1QB           USF2       
  STAT5A     ALL        MBL2D      ARG       PDLA1     C1QC           MIR10A     
  BMI1       HMOX1      MBPD       NCF2      CBR1      FCGR3A         IL1RAP     
  HSPA4      HMOX1D     LMO1       FLVCR1    AKR1A1    C1S            MIR320A    
  TGM2       NCF4       RBTN1      AXPC1     AKR1      FCGR1A         LTB4R2     
  NFKBIA     P40PHOX    RHOM1      PCARP     NQO1      FCGR2A         SETBP1     
  CD34       CGD3       LMO2       COPD      NOS3      FCGR2B         ULBP2      
  CALR       MKL1       RBTNL1     TCL4      NDUFS3    FCGR2C         BTG1       
  MIR34A     AMKL       RHOM2      ERBB4     NDUFS7    RRM2           KDM5A      
  XRCC3      MAL        TTG2       HER4      POR       DCK            MLLT3      
  PDGFRB     XK         CLLS1      ALS19     ABCC3     PRKAR2A        PHF6       
  SOCS1      MCLDS      SMAR       SGOL1     HPRT1     PRKAR1A        CD7        
  ABCC1      CYBB       NUMA1      SGO       TUBB      PDE3A          PTPRG      
  IFNA1      CGD        PICALM     SGO1      TUBA4A    1FNAR1         FCER1G     
  PIK3CG     AMCBX2     CALM       CAID      DHFR      FNTB           HULC       
  CYP2B6     IMD34      CLTH       THRB      FPGS      PDGFD          MIR196B    
  EIF4E      GATA1      LAP        ERBA2     TYMS      FLT1           MR1        
  XPC        GF1        ATA        THR1      ATIC      FLT4           RIN1       
  AURKB      ERYF1      AT1        PRTH      GGH       UGT1A3         ST3GAL4    
  PTPN6      NFE1       ZBTB16     MYD88     FOLR1     UGT1A4         FIP1L1     
  DNMT3A     XLTDA      ZNF145     MYD88D    IFNAR2    UGT1A9         MIR148B    
  BCL6       XLTT       PLZF       DCML      NS3       UGT2B7         MIR326     
  ALOX5      XLANP      KMT2A      MONOMAC   4A        UGT2B15        MIR486-1   
  ---------- ---------- ---------- --------- --------- -------------- ---------- ---------

###### 

Molecular docking between the 7 compounds of Qingdai and the corresponding candidate major targets.

  Compounds and targets      Protein-ligand interactions of the docking pose   Score
  -------------------------- ------------------------------------------------- -------
  Qingdainone, MAPK9                                                           4.306
  Qingdainone, MAPK10                                                          4.684
  Qingdainone, MAPK11                                                          4.435
  Qingdainone, MAPK11                                                          4.844
  Bisindigotin, MAPK9                                                          4.053
  Bisindigotin, MAPK10                                                         3.562
  Bisindigotin, MAPK11                                                         3.787
  Bisindigotin, MAPK14                                                         4.039
  Bisindigotin, F2                                                             4.598
  Isoindigo, FLT4                                                              7.117
  Isoindigo, PDGFRB                                                            5.516
  Isoindigo, FLT3                                                              7.780
  Indigotin, CDK1                                                              6.860
  Indirubin, CDK1                                                              2.633
  Indirubin, CDK4                                                              2.051
  Indirubin, CDK2                                                              2.583
  Indirubin, FLT3                                                              3.217
  Indirubin, GSK3B                                                             1.963
  Beta-sitosterol,AR                                                           8.365
  Beta-sitosterol, CYP19A1                                                     8.335
  Beta-sitosterol, LDLR                                                        4.981
  Beta-sitosterol, ESR1                                                        8.372
  Beta-sitosterol, ESR2                                                        8.321
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![The technical strategy of this research based on network pharmacology for deciphering Key pharmacological pathways of Qingdai acting on CML.](medscimonit-24-5668-g001){#f1-medscimonit-24-5668}

![Compound-Target network (C-T network). Network of 7 active compounds of Qingdai and 112 putative targets.](medscimonit-24-5668-g002){#f2-medscimonit-24-5668}

![GO enrichment analysis of the putative targets of Qingdai. The top 10 significantly enriched terms in CC, BP, and MF categories. Cellular component (**A**), Biological process (**B**), Molecular function (**C**).](medscimonit-24-5668-g003){#f3-medscimonit-24-5668}

![The network of putative targets of Qingdai and 26 KEGG pathways.](medscimonit-24-5668-g004){#f4-medscimonit-24-5668}

![The network of 195 major hubs based on their direct interactions, consisting of 195 nodes and 5943 edges. Nodes represent proteins. Colored nodes are query proteins and first shell of interactors. White nodes are second shell of interactors. Empty nodes are proteins of unknown 3D structure. Filled nodes have some 3D structure known or predicted. Edges represent protein-protein associations and line thickness indicates the strength of data support.](medscimonit-24-5668-g005){#f5-medscimonit-24-5668}

###### 

Active compounds and ADME parameters of Qingdai.

  No          Name              Structure   OB (%)   DL     Caco-2
  ----------- ----------------- ----------- -------- ------ --------
  MOL011100   Bisindigotin                  41.66    0.39   0.90
  MOL011332   Quindoline                    54.57    0.22   1.52
  MOL011335   Isoindigo                     94.30    0.26   0.79
  MOL001781   Indigotin                     38.20    0.26   0.83
  MOL001810   Qingdainone                   45.28    0.89   1.19
  MOL002309   Indirubin                     48.59    0.26   1.26
  MOL000358   Beta-sitosterol               36.91    0.75   1.32

OB -- oral bioavailability; DL -- druglikeness; Caco-2 -- Caco-2 permeability.

###### 

The 26 KEGG pathways associated with the putative targets of Qingdai.

  Term                                                                     Count   P-value
  ------------------------------------------------------------------------ ------- -------------
  hsa04914: Progesterone-mediated oocyte maturation                        10      2.93E-07
  hsa04080: Neuroactive ligand-receptor interaction                        13      1.57E-05
  hsa04115: p53 signaling pathway                                          7       8.78E-05
  hsa04060: Cytokine-cytokine receptor interaction                         12      1.03E-04
  hsa04110: Cell cycle                                                     8       3.91E-04
  hsa04510: Focal adhesion                                                 9       0.001437085
  hsa05210: Colorectal cancer                                              6       0.002152457
  hsa05200: Pathways in cancer                                             11      0.002692876
  hsa04062: Chemokine signaling pathway                                    8       0.004097191
  hsa04621: NOD-like receptor signaling pathway                            5       0.004583166
  hsa04620: Toll-like receptor signaling pathway                           6       0.004793465
  hsa05120: Epithelial cell signaling in *Helicobacter pylori* infection   5       0.006372769
  hsa04622: RIG-I-like receptor signaling pathway                          5       0.00742055
  hsa05212: Pancreatic cancer                                              5       0.007793627
  hsa04664: Fc epsilon RI signaling pathway                                5       0.010293415
  hsa04722: Neurotrophin signaling pathway                                 6       0.011255823
  hsa04020: Calcium signaling pathway                                      7       0.012206329
  hsa05215: Prostate cancer                                                5       0.016120746
  hsa04912: GnRH signaling pathway                                         5       0.022181176
  hsa04010: MAPK signaling pathway                                         8       0.026015669
  hsa04660: T cell receptor signaling pathway                              5       0.030365615
  hsa05214: Glioma                                                         4       0.03155056
  hsa04114: Oocyte meiosis                                                 5       0.032191066
  hsa05218: Melanoma                                                       4       0.042714992
  hsa04012: ErbB signaling pathway                                         4       0.040141341
  hsa04930: Type II diabetes mellitus                                      3       0.034045303

###### 

The 32 major targets information of Qingdai.

  ID      Target                                          Uniprot ID   Gene name   PDB ID
  ------- ----------------------------------------------- ------------ ----------- --------
  MT-1    Mitogen-activated protein kinase 8              P45983       MAPK8       IUKH
  MT-2    Estrogen receptor                               P03372       ESR1        1A52
  MT-3    Mitogen-activated protein kinase 14             Q16539       MAPK14      1A9U
  MT-4    Cyclin-dependent kinase 2                       P24941       CDK2        1AQ1
  MT-5    Vascular endothelial growth factor receptor 2   P35968       KDR         1VR2
  MT-6    Cyclin-dependent kinase 4                       P11802       CDK4        2W96
  MT-7    Androgen receptor                               P10275       AR          1E3G
  MT-8    Prothrombin                                     P00734       F2          1A2C
  MT-9    Cyclin-dependent kinase 1                       P06493       CDK1        4Y72
  MT-10   Glycogen synthase kinase-3 beta                 P49841       GSK3B       1GNG
  MT-11   Platelet-derived growth factor receptor beta    P09619       PDGFRB      1GQ5
  MT-12   Mitogen-activated protein kinase 9              P45984       MAPK9       3E7O
  MT-13   G2/mitotic-specific cyclin-B1                   P14635       CCNB1       2B9R
  MT-14   Mitogen-activated protein kinase 11             Q15759       MAPK11      3GC8
  MT-15   Receptor-type tyrosine-protein kinase FLT3      P36888       FLT3        1RJB
  MT-16   Cyclin-dependent kinase 6                       Q00534       CDK6        1BI7
  MT-17   Vascular endothelial growth factor receptor 1   P17948       FLT1        1FLT
  MT-18   Toll-like receptor 9                            Q9NR96       TLR9        3WPB
  MT-19   Cyclin-dependent-like kinase 5                  Q00535       CDK5        1H4L
  MT-20   C-C chemokine receptor type 5                   P51681       CCR5        4MBS
  MT-21   Alpha-synuclein                                 P37840       SNCA        2X6M
  MT-22   Low-density lipoprotein receptor                P01130       LDLR        1AJJ
  MT-23   Estrogen receptor beta                          Q92731       ESR2        1L2J
  MT-24   Glycogen synthase kinase-3 alpha                P49840       GSK3A       2DFM
  MT-25   Aromatase                                       P11511       CYP19A1     3EQM
  MT-26   Platelet-derived growth factor receptor alpha   P16234       PDGFRA      5GRN
  MT-27   Mitogen-activated protein kinase 10             P53779       MAPK10      1JNK
  MT-28   C-C chemokine receptor type 2                   P41597       CCR2        5T1A
  MT-29   Cyclin-dependent kinase 3                       Q00526       CDK3        ILFN
  MT-30   Microtubule-associated protein tau              P10636       MAPT        2ON9
  MT-31   ATP-binding cassette sub-family G member 2      Q9UNQ0       ABCG2       5NJ3
  MT-32   Vascular endothelial growth factor receptor 3   P35916       FLT4        4BSJ

###### 

The Top 20 enrichment pathways of 195 major hubs.

  Term                                                  Count   Value
  ----------------------------------------------------- ------- ----------
  hsa05200: Pathways in cancer                          70      2.22E-41
  hsa04010: MAPK signaling pathway                      34      5.88E-12
  hsa05220: Chronic myeloid leukemia                    29      9.85E-24
  hsa04062: Chemokine signaling pathway                 28      1.71E-11
  hsa04510: Focal adhesion                              28      9.51E-11
  hsa05215: Prostate cancer                             27      5.69E-19
  hsa04722: Neurotrophin signaling pathway              27      4.59E-15
  hsa04012: ErbB signaling pathway                      26      4.46E-18
  hsa04060: Cytokine-cytokine receptor interaction      26      5.61E-07
  hsa05210: Colorectal cancer                           23      4.84E-15
  hsa05221: Acute myeloid leukemia                      22      1.16E-17
  hsa04620: Toll-like receptor signaling pathway        22      2.94E-12
  hsa04660: T cell receptor signaling pathway           22      1.16E-11
  hsa04650: Natural killer cell mediated cytotoxicity   22      7.02E-10
  hsa04630: Jak-STAT signaling pathway                  22      1.23E-08
  hsa05212: Pancreatic cancer                           20      3.49E-13
  hsa04664: Fc epsilon RI signaling pathway             19      1.82E-11
  hsa04910: Insulin signaling pathway                   19      1.88E-07
  hsa05214: Glioma                                      18      4.43E-12
  hsa04110: Cell cycle                                  18      3.16E-07
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